弥漫性皮肤型系统性硬化症患者的治疗决策参与体验
SDM-Q-9显示决策过程被视为共享(中位81/100),但访谈揭示决策主要由风湿科医生主导,患者常被引导至特定方案。研究建议提供疾病特异性信息并探索患者偏好以优化决策。
要点
- dcSSc患者治疗决策多由风湿科医生主导,患者常被引导至特定选项。
- 患者因缺乏可及、可靠且SSc特异性信息而认可医生的强指导。
- 超半数患者因健康快速恶化及视HSCT为「圣杯」而感觉别无选择。
核心结论
- dcSSc治疗决策过程受缺乏疾病特异性治疗选项教育的不利影响。
- 建议探索患者偏好与疾病理解以优化决策并提供定制信息。
研究设计与样本
- 定性半结构化访谈研究,纳入HSCT前、后或选择其他治疗的患者。
- 采用主题分析,并以共享决策问卷(SDM-Q-9)评估共享决策。
主要发现
- SDM-Q-9显示决策过程被视为共享,中位评分81/100(范围49-100)。
- 访谈揭示决策主要由风湿科医生做出,患者常被引导至某一治疗选项。
- 患者因缺乏可及、可靠且SSc特异性信息而认可医生的强指导。
- 患者对结局和风险的期望存在差异。
- 超半数患者因健康快速恶化及视HSCT为「圣杯」而感觉别无选择只能接受HSCT。
关键数值与推荐
- SDM-Q-9共9个条目,中位评分81/100(范围49-100)。
- 访谈患者中5例为HSCT前,16例为HSCT后,4例选择其他治疗。
临床怎么用
- 临床决策中应主动探索患者偏好及其对疾病的理解。
- 提供可及、可靠且SSc特异性的治疗选项信息以支持决策。
- 识别患者因健康恶化或对HSCT期望过高而感知的「别无选择」。
局限性
- 定性研究设计,样本量有限,结果不宜直接外推。
- 仅纳入单中心或特定背景患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine the treatment decision-making process of patients with dcSSc in the context of haematopoietic stem cell transplantation (HSCT). METHODS: A qualitative semi-structured interview study was done in patients before or after HSCT, or patients who chose another treatment than HSCT. Thematic analysis was used. Shared decision-making (SDM) was assessed with the 9-item Shared Decision Making Questionnaire (SDM-Q-9). RESULTS: Twenty-five patients [16 male/nine female, median age 47 (range 27-68) years] were interviewed: five pre-HSCT, 16 post-HSCT and four following other treatment. Whereas the SDM-Q-9 showed the decision-making process was perceived as shared [median score 81/100 (range 49-100)], we learned from the interviews that the decision was predominantly made by the rheumatologist, and patients were often steered towards a treatment option. Strong guidance of the rheumatologist was appreciated because of a lack of accessible, reliable and SSc-specific information, due to the approach of the decision-making process of the rheumatologist, the large consequence of the decision and the trust in their doctor. Expectations of outcomes and risks also differed between patients. Furthermore, more than half of patients felt they had no choice but to go for HSCT, due to rapid deterioration of health and the perception of HSCT as 'the holy grail'. CONCLUSION: This is the first study that provides insight into the decision-making process in dcSSc. This process is negatively impacted by a lack of disease-specific education about treatment options. Additionally, we recommend exploring patients' preferences and understanding of the illness to optimally guide decision-making and to provide tailor-made information.
引用
- Spierings J, van Rhijn-Brouwer FCC, de Bresser CJM, et al. Treatment decision-making in diffuse cutaneous systemic sclerosis: a patient's perspective. Rheumatology (Oxford). 2020. PMID: 31808528. doi:10.1093/rheumatology/kez579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。